Earnouts, milestones, contingent value rights. Call them what you will but the use of these potential future payment clauses is rising across M&A to bridge the valuation gap, particularly in the biotech space. One problem: almost all of these triggers never hit. Here’s why.
To read the entire story, you must be logged in.
Please log in now or register with us.
